

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:**

**Drug Safety Labeling Changes -**

**Darvon (propoxyphene hydrochloride) capsules, Darvon-N (propoxyphene napsylate) tablets, and Darvocet-N (propoxyphene napsylate and acetaminophen) tablets**

According to MedWatch, FDA notified healthcare professionals that changes have been made to the labeling of Darvon, Darvon-N and Darvocet-N tablets. The revised labeling includes an approved risk evaluation and mitigation strategy (REMS) and states that:

- The new safety information pertains to the risk of overdose and the potential to affect cardiovascular events, including life-threatening arrhythmias, associated with the use of propoxyphene products.

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186885.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.